Introduction

Theregen, Inc. is a regenerative medicine company developing Anginera™, an epicardial patch, for cardiac applications. Anginera is a cell-based, three-dimensional human tissue patch that induces formation of mature blood vessels that leads to repair and restoration of regional heart function in humans. The company owns the exclusive worldwide rights to cardiovascular applications of Anginera, including all related technology and a supply agreement with Advanced BioHealing for manufacturing tissue for clinical trials.

Anginera is in advanced Phase I clinical development on two fronts: a safety study in patients with reversible myocardial ischemia undergoing Coronary Artery Bypass Graft (CABG) surgery, and in patients who receive a Left Ventricular Assist Device (LVAD) as a bridge to heart transplantation. In this study, valuable histological data has already been obtained from explanted study hearts. Based on early study data, Theregen has demonstrated for the first time in humans that Anginera induces growth of mature blood vessels in damaged cardiac tissue, stimulates tissue repair, and improves ventricular wall motion. The well-known biomedical venture capital firm, Sanderling Ventures, serves as Theregen's key investor and development advisor.